The AML patients who had c-KIT overexpression showed a significantly lower DFS rate compared to those with c-KIT low-expression, as the mean DFS in c-KIT overexpressors was 18.183 months compared to 24.212 months in those with c-KIT low-expression (P = 0.05). The gene discussed is KIT; the disease is acute myeloid leukemia.